Bayh-Dole’s “march-in” provision — which allows the government to mandate the relicensing of federally-funded innovations in limited circumstances — is often subject to misinterpretation. For nearly 20 years, critics have claimed that Bayh-Dole’s march-in right can be used as a price-setting mechanism — rather than a tool meant to ensure that private companies make good faith efforts to commercialize federally-funded inventions.
This video webinar, co-hosted by the Bayh-Dole Coalition and the Information Technology and Innovation Foundation (ITIF), will clarify the provision’s intent and explain once and for all how Bayh-Dole’s march-in right can and cannot be used. Speakers will detail how misusing march-in rights as a price-setting mechanism would eliminate research, development, and investment incentives across the technology transfer, venture capital, and life sciences industries.